IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Erika F. Rodriguez1 | Federico De Marchi1 | Parvez M. Lokhandwala1 | Deborah Belchis1 | Rena Xian1,2 | Christopher D. Gocke1,2 | James R. Eshleman1,2 | Peter Illei1 | Ming-Tseh Li1

1Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Correspondence
Erika F. Rodriguez, Department of Pathology, Johns Hopkins University, Carnegie 469 – Pathology, 600 North Wolfe Street, Baltimore, MD 21287, USA.
Email: erodri17@jhmi.edu

Funding information
This retrospective analysis for quality improvement was supported by 1UM1CA186691-01 from the National Cancer Institute of USA.

Abstract
Background: Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2-mutated non–small cell lung cancers (NSCLCs), however, are limited.

Methods: We evaluated IDH1/2 mutations in 1,924 NSCLC specimens (92% adenocarcinaoma) using a next-generation sequencing assay.

Results: Retrospective quality assessments identified false detection of IDH1 c.395G>A (p.R132H) resulting from cytosine deamination (C:G→T:A) artifact in one specimen. IDH1/2 mutations were detected in 9 (0.5%) adenocarcinomas taken by fine-needle aspiration (n = 3), thoracentesis (n = 2) or core biopsy (n = 4). All nine adenocarcinomas showed high-grade features. Extensive clear cell change, however, was not observed. High expression (50% or greater) of PD-L1 was observed in two of five specimens examined. IDH1/2 mutations were associated with old age, smoking history, and coexisting KRAS mutation. Lower than expected variant allele frequency of IDH1/2 mutants and coexistence of IDH1/2 mutations with known trunk drivers in the BRAF, EGFR, and KRAS genes suggest they could be branching drivers leading to subclonal evolution in lung adenocarcinomas. Multiregional analysis of an adenocarcinoma harboring two IDH2 mutations revealed parallel evolution originating from a KRAS-mutated lineage, further supporting subclonal evolution promoted by IDH1/2 mutations.

Conclusions: IDH1/2 mutations in NSCLCs are uncommon. They occur in adenocarcinomas with high-grade features and may be branching drivers leading to subclonal evolution. Accumulation of more IDH1/2-mutated NSCLCs is needed to clarify their clinicopathological characteristics and implications for targeted therapy.

Keywords
cytosine deamination, IDH1, IDH2, lung cancers, parallel evolution
1 | INTRODUCTION

Mutational profiling identifies genomic alterations for targeted therapy in metastatic non–small cell lung cancers (NSCLCs). Several targeted therapeutic agents have been approved for metastatic NSCLCs with EGFR mutations, BRAF p.V600E, ALK translocations, and ROS1 translocations.1,2 Mutational profiling of these genomic alterations is considered standard of care for patients with metastatic NSCLCs.3 Integrated multiplatform analyses including whole-exon sequencing and whole-genome sequencing have uncovered additional genomic alterations in NSCLCs with potential implications for targeted therapy, such as ERBB2 mutations, MET mutations and translocations of the RET, NTRK1, NTRK2, and NTRK3 genes.1,2

IDH1 mutations involving codon 132 and IDH2 mutations involving codons 140 and 172 occur in a variety of human cancers, including acute myeloid leukemia (AML), diffuse gliomas, cholangiocarcinoma, and chondrosarcoma.4-11 IDH1 and IDH2 (IDH1/2) mutations were also reported in NSCLCs with a much lower incidence (0.4%-1.1%).12-14 IDH1/2 mutants lead to accumulation of D-2-hydroxyglutarate through neoenzymatic conversion, and subsequent oncogenic effects including epigenetic alterations.15,16 IDH2 inhibitor (Enasidenib or AG-221) and IDH1 inhibitor (Ivosidenib or AG-120) have been approved by the Food and Drug Administration in the United States for targeted therapy of AML.6,7 Several clinical trials of IDH1/2 inhibitors for advanced solid tumors, such as NCT02073994 (AG-120 for IDH1 mutations), NCT02746081 (BAY1436032 for IDH1 mutations), and NCT02481154 (AG-881 for IDH2 mutations) are ongoing. Clinical pharmacokinetics and pharmacodynamics studies have shown robust and persistent inhibition of plasma D-2-hydroxyglutarate by oral ivosidenib.17

In this study for quality assessment, next-generation sequencing (NGS) was examined in a large cohort of NSCLC specimens to elucidate the incidence of IDH1/2 mutations and the clinicopathological and molecular characteristics of IDH1/2-mutated NSCLCs.

2 | MATERIALS AND METHODS

2.1 | Materials

NGS results from 1924 lung cancer specimens (1778 adenocarcinomas, 24 adenosquamous carcinomas, 12 adenocarcinomas in situ, and 110 NSCLCs) submitted between April 2013 and December 2018 were analyzed for mutations in IDH1 and IDH2 genes. For multiple specimens taken from the same tumor (such as biopsy and resection specimens, or primary and metastatic tumor specimens) and showing an identical mutation status, only one specimen was included. Specimens with prior EGFR tyrosine kinase inhibitor therapy were also excluded. Accompanied hematoxylin and eosin–stained slides were reviewed by a pulmonary pathologist (PI) and/or a molecular pathologist (MTL). DNA was isolated from formalin-fixed paraffin-embedded (FFPE) tissues using Pinpoint reagents (ZymoResearch) and purified using QIAmp DNA kit (Qiagen) as described previously.18 After April 2017, DNA was isolated from FFPE tissues using Tissue Preparation System (Siemens) according the manufacturer’s protocol. Concentration of DNA was determined by Qubit 2.0 Fluorometer (Life Technologies). The Johns Hopkins Institutional Review Board granted approval to this study.

2.2 | Next-generation sequencing (NGS)

NGS was conducted using AmpliSeq Cancer Hotspot Panel (v2) (Life Technologies) for targeted multigene amplification, as described previously.18,19 Mutations were identified and annotated through both Torrent Variant Caller (Life Technologies) and direct visual inspection of the binary sequence alignment/map file using the Broad Institute’s Integrative Genomics Viewer (IGV) (http://www.broad institute.org/igv/) as described previously.20 In addition to IDH1 ( NM_005896) and IDH2 ( NM_002168), mutations in the AKT1 ( NM_005163), BRAF ( NM_004333), EGFR ( NM_005228), ERBB2 ( NM_004448), KRAS ( NM_033360), NRAS ( NM_002528), and PIK3CA ( NM_006218) genes were analyzed for each specimen. The analytic performance characteristics of this assay for lung cancers have been reported previously.19 During our validation of this NGS assay, a cutoff of background noise at 2% was chosen for single-nucleotide variations.21

2.3 | Immunohistochemical stains

Immunohistochemical stains for TTF1, Napsin A, and programmed death ligand 1 (PD-L1) were performed as routine clinical assays using Ventana XT (Ventana Medical Systems) and Leica Bond III (Leica Microsystems) automated immunohistochemistry platform as described previously.22 The monoclonal antibody clone 22C3 (KEYTRUDA) (Neogenomics) and OptiView Detection System (Ventana Medical Systems) were used for PD-L1 staining. High expression is defined as 50% or greater Tumor Proportion Score.

2.3.1 | Statistical analysis

The Fisher exact test or χ² test was performed to calculate P values.
3 | RESULTS

3.1 | IDH1/2 mutations in lung adenocarcinomas

NGS detected 11 IDH1/2 mutations in 10 specimens (Table 1). These included 8 specimens with an IDH1 mutation (4 with p.R132L or c.395G>T, 3 with p.R132H or c.395G>A, 1 with p.R132G or c.394C>G), 1 specimen with an IDH2 mutation (p.R172S or c.516G>T), and 1 specimen with 2 IDH2 mutations (p.R140Q or c.419G>A and p.R172M or c.515G>T). The variant allele frequency (VAF) was less than 5% in 4 specimens, including cases 3 and 10 harboring a cytosine deamination change (p.R132H or c.395G>A). Repeat of NGS showed a concordant VAF (2.9% p.R132H in case 3, 3.3% p.R132G in case 5, 3.5% p.R132L in case 6, and 4.5% p.R132H in case 10). DNA was isolated from the adjacent nonneoplastic tissues of case 3 (one subarea with no tumors) and case 10 (two separate subareas with no tumors). NGS showed c.395G>A in both nonneoplastic and neoplastic subareas of case 10 (Figure 1A,B), but only in the neoplastic subarea of case 3 (Figure 2A,B). Analysis of the entire NGS panel revealed a TP53 p.C242W (c.726C>G) in the neoplastic subarea, but not the two nonneoplastic subareas of case 10 (Figure 1C,D). The results indicated cytosine deamination artifact of case 10 leading to a false detection of IDH1 c.395G>A. This specimen was excluded for further analysis of IDH1/2-mutated NSCLCs.

IDH1/2 mutations were detected in nine (0.5%) of 1924 patients with NSCLCs (Table 2). All nine patients were diagnosed as adenocarcinoma. There were three males and six females. The age ranged from 55 to 89 years with a median of 78 years. Seven (78%) of nine patients are 70 years or older. Six were current or former smokers and two were never smokers. Seven patients presented as a newly diagnosed lung cancer (3 with stage IA, 1 with stage IIB, and 3 with stage IV). Case 9 revealed a residual lung adenocarcinoma, 18 months after the initial diagnosis of stage IIB.

All specimens had a coexisting driver mutation in another gene—seven specimens with a coexisting KRAS mutation, one with an EGFR mutation, and one with a PIK3CA mutation. IDH1/2 mutations were not detected in AKTI-, BRAF-, ERBB2-, or NRAS-mutated NSCLCs. The incidence of IDH1/2 mutations was significantly higher in KRAS-mutated NSCLCs (n = 656) as compared with KRAS wild-type NSCLCs (n = 1268) (1.1% vs 0.2%, P = .009). Six (86%) of seven patients with coexisting KRAS and IDH1/2 mutations were 70 years or older, compared to 278 (43%) of 649 patients with only a KRAS mutation (P = .047).

3.2 | Histomorphology and immunophenotypes of IDH1/2-mutated lung adenocarcinomas

Specimens were taken by fine-needle aspiration (FNA) of lung or lymph node (n = 3), thoracentesis of pleural effusion (n = 2), or core biopsy of lung or pleura (n = 4). Histomorphology of the core biopsy specimens and the cell blocks of FNA or thoracentesis specimens were reviewed by a cytopathologist (ER) and a pulmonary pathologist (PI). Necrosis was seen in three biopsy specimens and two FNA blocks of FNA or thoracentesis specimens were reviewed.

### TABLE 1 Coexisting mutations in lung adenocarcinomas with IDH1/2 mutations

| Cases | Tumor %a | 7-gene profilingb,c | IDH1/IDH2c |
|-------|----------|---------------------|-----------|
| 1     | 21%-40%  | Kras p.Q61H (10%)   | IDH1 p.R132H (25%, 558/741) |
| 2     | 11%-30%  | Kras p.G12d (7.9%)  | IDH1 p.R132L (11%, 938/8452) |
| 3     | 51%-70%  | Egfr p.E746-A750del (33%) | IDH1 p.R132H (3.0%, 174/5707) |
| 4     | 71%-90%  | Kras p.G12c (49%)   | IDH1 p.R132L (33%, 3360/10307) |
| 5     | 31%-50%  | Pik3ca p.E542k (13%) | IDH1 p.R132G (2.8%, 162/5841) |
| 6     | 41%-60%  | Kras p.G12v (18%)   | IDH1 p.R132L (3.8%, 290/7730) |
| 7     | 41%-60%  | Kras p.G12d (27%)   | IDH1 p.R132L (19%, 503/2649) |
| 8     | 51%-70%  | Kras p.G12d (34%)   | IDH2 p.R172s (13%, 282/2094) |
| 9     | 41%-60%  | Kras p.G12v (53%)   | IDH2 p.R140q (13%, 260/2011) |
| 10    | 11%-30%  | No mutation         | IDH1 p.R132H (4.6%, 109/2351)d |

aEstimated tumor cellularity.
bAKTI, BRAF, EGFR, ERBB2, Kras, NRAS, and PIK3CA.
cPercentages and numbers in the parentheses indicate variant allele frequency and read depth of next-generation sequencing. The numerator is the variant read number and the denominator is the total read number.
dQuality assessment revealed c.395G>A (p.R132H) change resulting from cytosine deamination artifact. This specimen was excluded for further analysis.
specimens. All five cytology specimens were characterized by high-grade cytology, such as high nuclear to cytoplasmic ratio, marked pleomorphism and/or prominent nucleoli (Figure 3A). All four biopsy specimens also showed high-grade histopathology with marked pleomorphism (n = 4) and a predominantly solid pattern (n = 3) (Figure 3B). Extensive clear cell change, as described by Toth et al, was not observed in all nine adenocarcinomas.

Tumor cells were immunoreactive with TTF1 in eight of eight specimens examined and immunoreactive
with Napsin A in six of six specimens examined, confirming a diagnosis of lung adenocarcinoma (Table 2). Immunohistochemical stains were not performed for case 3 taken from the right upper lobe and harboring an EGFR exon 19 deletion mutation, supporting a diagnosis of lung adenocarcinoma. High expression (50% or greater) of PD-L1 was observed in two of five specimens examined.

### Table 2: Lung adenocarcinomas with IDH1 or IDH2 mutations

| Cases | Age/gender | Smoking | Specimens | Stage<sup>b</sup> | HG<sup>c</sup> | TTF1/napsin A | PD-L1 |
|-------|------------|---------|-----------|------------------|--------------|--------------|--------|
| 1     | 67/F       | Yes     | LLL (FNA) | IA               | Yes          | Positive/Positive | Not done |
| 2     | 70/F       | Yes     | Lung, station 7 (FNA) | IIIB           | Yes          | Positive/Positive | Not done |
| 3     | 55/F       | No      | RLL (Bx)  | IA               | Yes          | Not done/Not done | Not done |
| 4     | 78/M       | No      | LN, station 7 (FNA) | IV             | Yes          | Positive/Not done | 1%     |
| 5     | 87/F       | Yes     | RUL (Bx)  | IA               | Yes          | Positive/Not done | 85%    |
| 6     | 89/M       | Yes     | Pleural effusion (TC) | IV             | Yes          | Positive/Positive | >95%   |
| 7     | 81/F       | No      | Pleura (Bx) | VK             | NK           | Positive/Not done | 40%    |
| 8     | 83/F       | Yes     | Pleural effusion (TC) | IV             | Yes          | Positive/Positive  | <1%    |
| 9     | 71/M       | Yes     | RUL (Bx)  | IIIB            | Yes          | Positive/Positive | Not done |

Abbreviations: Bx, biopsy; F, female; FNA, fine-needle aspiration; LLL, left lower lobe; LN, lymph node; M, male; NK, not known; RLL, right lower lobe; RUL, right upper lobe; TC, thoracentesis.

<sup>a</sup>Immunohistochemical stains were performed using another specimen taken from the same tumor.

<sup>b</sup>Staging at initial diagnosis of lung cancer.

<sup>c</sup>High-grade (HG) histopathology or cytopathology.

### Figure 3
High-grade features of IDH1/2 mutated lung adenocarcinomas (hematoxylin and eosin 600X for 3A, 3B, 3D and 3F and 200X for 3C and 3E). A, Cell block section (case 1 shows adenocarcinoma with marked pleomorphism and necrosis. B, Core biopsy of pleura (case 5) shows adenocarcinoma with solid growth pattern, marked pleomorphism, mitosis and necrosis. C-D, High-grade adenocarcinoma component of case 3 containing an IDH1 mutation. E-F, well-differentiated adenocarcinoma component of case 3 harboring an EGFR mutation.
3.3 | Subclonal IDH1/2 mutations

VAFs of IDH1/2 mutants were higher than or concordant with those of KRAS mutants in cases 1 and 2, but were lower than those of KRAS, EGFR, or PIK3CA mutants in the remaining cases (Figure 4). The findings suggest a higher incidence of mutant allele–specific imbalance of the IDH1, EGFR, or PIK3CA mutations or presence of subclonal tumor populations harboring IDH1/2 mutations. The observations of less than 5% VAF of the IDH1 mutation in cases 3, 5, and 6 in a context of 51%-70%, 31%-50%, and 41%-60% estimated tumor cellularity and 33%, 13%, and 18% VAF of the coexisting EGFR, KRAS, or PIK3CA mutation suggest presence of IDH1 mutation in a tumor subpopulation.

Subclonal evolution is also supported by examination of the resection specimen taken from case 3 at 2 months after biopsy. While NGS revealed 31% EGFR p.E746_A750del mutation and 3.0% IDH1 p.R132H mutation in the biopsy specimen, the resection specimen showed the same EGFR mutation at 25%, but no IDH1 mutation (Figure 2). Furthermore, the biopsy specimen showed a high-grade features (Figure 3C,D), but the resection specimen showed a well-differentiated adenocarcinoma with a lepidic growth pattern.

3.4 | Parallel evolution of IDH2 mutations

Case 9 was obtained 18 months after the initial diagnosis and treatment with chemotherapy and immune checkpoint blockade therapy (nivolumab). NGS analysis of this fragmented biopsy specimen containing approximately 41%-60% estimated tumor cellularity revealed a KRAS mutation (VAF: 53%) and two IDH2 mutations (VAFs: 13% for p.R140Q and 17% for p.R172M) within different alleles (Table 1). DNA was isolated from five randomly selected subareas showing similar histomorphology. The VAF ratio of p.R140Q and p.R172M was 21 (19% vs 0.9%) (Figure 5A,C), 6.8 (23% vs 3.4%), 2.3 (16% vs 6.9%), 0.99 (7.2% vs 7.3%), and 0.41 (15% vs 36%) (Figure 5B,D), respectively. Variation in VAF ratios from area to area support that the two IDH2 mutations were present in different subpopulations harboring the same trunk KRAS driver mutation.

4 | DISCUSSION

In this study with nearly 2000 NSCLC specimens, we confirmed a low incidence of IDH1/2 mutations (0.5%), similar to those reported from MSK-IMPACT (0.4%) and The Cancer Genome Atlas (TCGA) (0.4%) and relatively lower than that reported by Toth et al (1.1%).12-14 The associations of IDH1/2 mutations with smoking history (75%), 70 years or older (78%), and coexisting KRAS mutation (78%) are consistent with those previously observed (94%, 80%, and 69%, respectively).12-14 All 9 IDH1/2-mutated lung adenocarcinomas showed high-grade histopathology and/or cytopathology. Extensive clear cell change has been previously reported in lung adenocarcinomas with either IDH1 p.R132C or p.R132L mutation,14 but not in nine lung adenocarcinomas in this study, including four with an IDH1 p.R132L mutation.

Tumor heterogeneity has important clinical applications in targeted therapy.23,24 Trunk (initiating) driver mutations initiate the development of a founding cancer cell. Subsequently, branching driver mutations promote subclonal evolution. Therefore, trunk drivers are present in each cancer cell of the primary and metastatic tumors, while branching drivers may be present in a dominant subpopulation or a minor subclone. Targeting a mutation present only in a minor subclone likely results in a shorter progression-free survival, even though the initial efficacy is observed. A combinatorial therapy to include trunk drivers, if present, for targeting may provide better treatment outcomes. We have previously shown that lower than expected VAF indicates intratumor heterogeneity while higher than expected VAF indicates mutant allele–specific imbalance.25 In this study, the high incidence of coexisting KRAS and EGFR driver mutations and the lower than expected IDH1/2 VAF suggest that IDH1/2 mutations may be branching drivers promoting subclonal progression of lung adenocarcinomas.

By tracking the evolution of lung adenocarcinomas, most BRAF, EGFR, and KRAS activating mutations are trunk drivers.26 These trunk drivers are usually mutually exclusive, although rare cases with coexisting EGFR and KRAS mutations have been reported.27 In contrast, TP53 and PIK3CA mutations are branching drivers and can be seen in BRAF-, EGFR-, or KRAS-mutated lung adenocarcinomas. In a total of 25 IDH1/2-mutated lung adenocarcinomas reported by Toth et al, TCGA, MSK-IMPACT, and this study, known trunk
drivers were seen in 23 cases. These included 18 cases with a \textit{KRAS} mutation, four cases with an \textit{EGFR} mutation, and one case with \textit{BRAF} p.V600E. Coexistence of \textit{IDH1/2} mutations with trunk drivers within different genes suggests \textit{IDH1/2} mutations are branching drivers. In case 3 from our cohort, the observation of an \textit{EGFR} mutation in both the biopsy and resection specimens of the same tumor, but the presence of \textit{IDH1} mutation only in the biopsy specimen also supports that the \textit{IDH1} mutation was a branching driver occurring during the subclonal evolution in lung adenocarcinoma. Immunohistochemical stains could also be helpful to identify tumor heterogeneity of the \textit{IDH1} p.R132H mutant.

Mutations within the same signature transduction pathway are redundant and, therefore, most mutually exclusive. Detection of coexisting mutations within the same pathway raises the concern for potential laboratory errors. In a previous study for quality assessment, we confirmed that \textit{KRAS} and \textit{NRAS} mutations may be present in the same population or different subpopulations of colorectal cancers according to an operating procedure proposed for validation of unexpected coexisting mutations. Concurrent \textit{IDH1} and \textit{IDH2} mutations have been reported in two AMLs, four anaplastic gliomas, and three chondrosarcomas. Whether multiple \textit{IDH1/2} mutations occurred in the same or different tumor subpopulations was not described. In this study, multiregional analyses of case 9 support the presence of two distinct \textit{IDH2} mutations in different subpopulations harboring the same trunk driver \textit{KRAS} mutation.

Parallel evolution in neoplasms refers to evolution of distinct subpopulations from a common ancestral clone as a consequence of independent mutations affecting the same gene or genes in the same pathway. Parallel evolution has been shown in a variety of neoplasms, including lung cancers involving genetic alterations in the \textit{MUC1}, \textit{CDK4}, \textit{CHD8}, and \textit{NKX2-1} genes. Results of multiregional analyses in case 9 indicate paralleled evolution involving the \textit{IDH2} gene and support subclonal evolution promoted by two \textit{IDH2} mutations as branching drivers.

Previous studies have confirmed the role of \textit{IDH1} and \textit{IDH2} driver mutations in tumorigenesis of AML and gliomas. In vitro studies showed \textit{IDH1} p.R132H mutation enhances migration and proliferation of NSCLC cells through downregulation of fibulin 5 by hypermethylation of the promoter. In lung cancers, plasma \textit{IDH1} and \textit{IDH2} proteins are elevated and could be novel biomarkers for diagnosis of NSCLCs. A germline variant (rs11540478) within the \textit{IDH2} gene is associated with an increased risk of lung cancers. Cannataro et al have proposed a novel concept, the cancer effect size of genetic alterations, to estimate the intensity of selective advantage to cancer cells. As expected, mutations of \textit{IDH1} codon 132 show a very high effect size (greater than $10^6$ or $10^7$) in lower-grade glioma of the brain. \textit{IDH1} p.R132C also shows a relatively higher effect size ($10^4$-$10^5$) in lung adenocarcinomas. These findings suggest \textit{IDH1/2} mutations may confer selective advantage for clonal evolution in lung adenocarcinomas.

\textit{IDH1} and \textit{IDH2} mutations are detected in approximately 60%-80% and 1%-5% of patients with WHO grades II-III astrocytoma or oligodendroglioma and are predominantly \textit{IDH1} p.R132H (>90%). In gliomas of the brain, \textit{IDH1/2} mutations are trunk drivers to confer cancer initiation and are favorable prognostic markers. Combined analysis of 26 \textit{IDH1/2} mutations in NSCLCs reported in the previous and current studies revealed predominantly \textit{IDH1} p.R132C (35%) and p.R132L.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure5.png}
\caption{Multiregional analysis of KRAS mutated lung adenocarcinoma harboring two IDH2 mutations. In case 9, subarea 2 showed a dominant population with IDH2 p.R140Q and subarea 3 showed a dominant population with IDH2 p.R172M mutation. Percentage in parentheses indicates variant allele frequency.}
\end{figure}
cytosine deamination changes induced by formalin fixation or thermocycling of polymerase chain reaction is a major cause of background noise in both Sanger sequencing and NGS. Pretreatment of DNA specimens with uracil-N-glycosylase can reduce the level of cytosine deamination artifact. During our validation of this NGS panel, we have shown that background noise is consistent with spontaneous and formalin-induced cytosine deamination changes. Therefore, a cutoff of background noise at 2% was chosen for single-nucleotide variations. In our daily routine practice, background noise resulting from cytosine deamination changes is often less 2%. However, up to 2%-5% of cytosine deamination artifact occurring at multiple-nucleotide positions can be observed when the DNA input is suboptimal (usually less than 10 ng), consistent with previous observations that the chance of cytosine deamination artifact was inversely correlated with input of DNA quantity for sequencing. Repeat of NGS often shows a low level of cytosine deamination changes occurring at other nucleotide positions. The observation of IDH1 c.359G>A (p.R132H) in case 10 was uncommon for cytosine deamination artifacts. In this specimen, cytosine deamination changes with frequency of 2% or more at other nucleotide positions were not observed and repeat of NGS showed persistent IDH1 c.359G>A change. However, NGS analyses of two subareas containing no tumor cells also show c.359G>A change indicating a false detection of IDH1 c.395G>A.

Although the incidence of IDH1/2 mutations is only 0.4%-1.1% in NSCLCs, it is worthwhile to investigate IDH1/2 inhibitors because of the high prevalence of lung cancers in the United States and worldwide. On the other hand, IDH1/2 mutations may be branching drivers leading to subclonal evolution, which may affect the benefit of IDH1/2 inhibitors. Accumulation of more IDH1/2-mutated NSCLCs is needed to elucidate their clinicopathological characteristics and implications for targeted therapy.

CONFLICT OF INTEREST
All authors declare no conflict of interest.

AUTHORS’ CONTRIBUTION
Erika Rodriguez and Federico De Marchi (First authors): conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, and writing original draft. Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, and Peter Illei: investigation, resources, data curation, and editing manuscript. Ming-Tseh Li: conceptualization, methodology, validation, formal analysis, investigation, resources, data curation, writing review and editing, visualization, supervision, and project administration.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Erika F. Rodriguez https://orcid.org/0000-0001-6757-1172

REFERENCES
1. Reck M, Rabe KF. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377:849-861.
2. Brown NA, Aisner DL, Oxnard GR. Precision medicine in non-small cell lung cancer: current standards in pathology and biomarker interpretation. Am Soc Clin Oncol Educ Book. 2018;38:708-715.
3. Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321-346.
4. Marcucci G, Maharry K, Wu YZ, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348-2355.
5. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636-3643.
6. Stein EM, DiNardo CD, Polleyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722-731.
7. DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386-2398.
8. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendrogial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-474.
9. Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH1) and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72-79.
10. Kipp BR, Voss JS, Kerr SE, et al. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma. Hum Pathol. 2012;43:1552-1558.
11. Amary MF, Basci K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334-343.
12. Gutman DA, Cobb J, Somanna D, et al. Cancer digital slide archive: an informatics resource to support integrated in silico analysis of TCGA pathology data. J Am Med Inform Assoc. 2013;20:1091-1098.
13. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*. 2017;23:703-713.
14. Toth LN, de Abreu FB, Tafe LJ. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations. *Hum Pathol*. 2018;78:138-143.
15. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. *Nature*. 2010;465:966.
16. Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Lokhandwala PM, et al. IDH1/2 mutations predict shorter survival in chondrosarcoma. *J Cancer*. 2018;9:998-1005.
17. Fan B, Mellinghoff IK, Wen PY, et al. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. *Invest New Drugs*. 2020;38(2):433-444.
18. Zheng G, Lin M-T, Lokhandwala PM, et al. Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next-generation sequencing. *Cancer Cytopathol*. 2016;124:744-753.
19. Illei PB, Belchis D, Tseng L-H, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. *Oncotarget*. 2017;8:96684-96696.
20. Thorvaldsdottir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. *Brief Bioinform*. 2013;14:178-192.
21. Lin M-T, Mosier SL, Thiess M, et al. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing. *Am J Clin Pathol*. 2014;141:856-866.
22. Cowan ML, Li QK, Illei PB. CDX-2 expression in primary lung adenocarcinoma. *Appl Immunohistochem Mol Morphol*. 2016;24:16-19.
23. Gertlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N Engl J Med*. 2012;366:883-892.
24. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LAr, Kinzler KW. Cancer genome landscapes. *Science*. 2013;339:1546-1558.
25. Haley L, Tseng L-H, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. *Mod Pathol*. 2015;28:1390-1399.
26. Jamal-Hanjani M, Wilson GA, McGranahan N, et al. Tracking the evolution of non-small-cell lung cancer. *N Engl J Med*. 2017;376:2109-2121.
27. De Marchi F, Haley L, Fryer H, et al. Clinical validation of coexpressing activating mutations within EGFR, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase pathways in lung cancers. *Arch Pathol Lab Med*. 2019;143:174-182.
28. Tseng LH, De Marchi F, Pallavajjalla A, et al. Clinical validation of discordant trunk driver mutations in paired primary and metastatic lung cancer specimens. *Am J Clin Pathol*. 2019;152(5):570-581.